614 related articles for article (PubMed ID: 17473175)
1. Human pharmacology of naproxen sodium.
Capone ML; Tacconelli S; Sciulli MG; Anzellotti P; Di Francesco L; Merciaro G; Di Gregorio P; Patrignani P
J Pharmacol Exp Ther; 2007 Aug; 322(2):453-60. PubMed ID: 17473175
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects.
Capone ML; Tacconelli S; Sciulli MG; Grana M; Ricciotti E; Minuz P; Di Gregorio P; Merciaro G; Patrono C; Patrignani P
Circulation; 2004 Mar; 109(12):1468-71. PubMed ID: 15037526
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects.
Capone ML; Sciulli MG; Tacconelli S; Grana M; Ricciotti E; Renda G; Di Gregorio P; Merciaro G; Patrignani P
J Am Coll Cardiol; 2005 Apr; 45(8):1295-301. PubMed ID: 15837265
[TBL] [Abstract][Full Text] [Related]
4. Increased platelet sensitivity among individuals with aspirin resistance - platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy.
Guthikonda S; Mangalpally K; Vaduganathan M; Patel R; Delao T; Bergeron AL; Dong JF; Lev EI; Kleiman NS
Thromb Haemost; 2008 Jul; 100(1):83-9. PubMed ID: 18612542
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease.
Sciulli MG; Renda G; Capone ML; Tacconelli S; Ricciotti E; Manarini S; Evangelista V; Rebuzzi A; Patrignani P
Clin Pharmacol Ther; 2006 Aug; 80(2):115-25. PubMed ID: 16890573
[TBL] [Abstract][Full Text] [Related]
6. Effect of COX-1/COX-2 inhibition versus selective COX-2 inhibition on coronary vasodilator responses to arachidonic acid and acetylcholine.
Gross GJ; Moore J
Pharmacology; 2004 Jul; 71(3):135-42. PubMed ID: 15161995
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.
Gurbel PA; Bliden KP; DiChiara J; Newcomer J; Weng W; Neerchal NK; Gesheff T; Chaganti SK; Etherington A; Tantry US
Circulation; 2007 Jun; 115(25):3156-64. PubMed ID: 17562955
[TBL] [Abstract][Full Text] [Related]
8. Cyclooxygenase-1 haplotype C50T/A-842G does not affect platelet response to aspirin.
Pettinella C; Romano M; Stuppia L; Santilli F; Liani R; Davì G
Thromb Haemost; 2009 Apr; 101(4):687-90. PubMed ID: 19350112
[TBL] [Abstract][Full Text] [Related]
9. Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences.
Anzellotti P; Capone ML; Jeyam A; Tacconelli S; Bruno A; Tontodonati P; Di Francesco L; Grossi L; Renda G; Merciaro G; Di Gregorio P; Price TS; Garcia Rodriguez LA; Patrignani P
Arthritis Rheum; 2011 Mar; 63(3):850-9. PubMed ID: 21360514
[TBL] [Abstract][Full Text] [Related]
10. Impact of naproxen sodium at over-the-counter doses on cyclooxygenase isoforms in human volunteers.
Hinz B; Cheremina O; Besz D; Zlotnick S; Brune K
Int J Clin Pharmacol Ther; 2008 Apr; 46(4):180-6. PubMed ID: 18397691
[TBL] [Abstract][Full Text] [Related]
11. Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease.
Renda G; Tacconelli S; Capone ML; Sacchetta D; Santarelli F; Sciulli MG; Zimarino M; Grana M; D'Amelio E; Zurro M; Price TS; Patrono C; De Caterina R; Patrignani P
Clin Pharmacol Ther; 2006 Sep; 80(3):264-74. PubMed ID: 16952493
[TBL] [Abstract][Full Text] [Related]
12. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2.
McAdam BF; Catella-Lawson F; Mardini IA; Kapoor S; Lawson JA; FitzGerald GA
Proc Natl Acad Sci U S A; 1999 Jan; 96(1):272-7. PubMed ID: 9874808
[TBL] [Abstract][Full Text] [Related]
13. COX-2 is not involved in thromboxane biosynthesis by activated human platelets.
Patrignani P; Sciulli MG; Manarini S; Santini G; Cerletti C; Evangelista V
J Physiol Pharmacol; 1999 Dec; 50(4):661-7. PubMed ID: 10639016
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacology of cyclooxygenase inhibition and pharmacodynamic interaction with aspirin by floctafenine in Thai healthy subjects.
Maenthaisong R; Tacconelli S; Sritara P; Del Boccio P; Di Francesco L; Sacchetta P; Archararit N; Aryurachai K; Patrignani P; Suthisisang C
Int J Immunopathol Pharmacol; 2013; 26(2):403-17. PubMed ID: 23755755
[TBL] [Abstract][Full Text] [Related]
15. Platelet inhibitory effects of OTC doses of naproxen sodium compared with prescription dose naproxen sodium and low-dose aspirin.
Schiff M; Hochberg MC; Oldenhof J; Brune K
Curr Med Res Opin; 2009 Oct; 25(10):2471-7. PubMed ID: 19678751
[TBL] [Abstract][Full Text] [Related]
16. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance".
Santilli F; Rocca B; De Cristofaro R; Lattanzio S; Pietrangelo L; Habib A; Pettinella C; Recchiuti A; Ferrante E; Ciabattoni G; Davì G; Patrono C
J Am Coll Cardiol; 2009 Feb; 53(8):667-77. PubMed ID: 19232899
[TBL] [Abstract][Full Text] [Related]
17. Prostacyclin, thromboxane A and the effect of low-dose ASA in pregnancies at high risk for hypertensive disorders.
Vainio M; Riutta A; Koivisto AM; Mäenpää J
Acta Obstet Gynecol Scand; 2004 Dec; 83(12):1119-23. PubMed ID: 15548142
[TBL] [Abstract][Full Text] [Related]
18. Dose- and time-dependent antiplatelet effects of aspirin.
Perneby C; Wallén NH; Rooney C; Fitzgerald D; Hjemdahl P
Thromb Haemost; 2006 Apr; 95(4):652-8. PubMed ID: 16601836
[TBL] [Abstract][Full Text] [Related]
19. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.
Greenberg HE; Gottesdiener K; Huntington M; Wong P; Larson P; Wildonger L; Gillen L; Dorval E; Waldman SA
J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1509-15. PubMed ID: 11185674
[TBL] [Abstract][Full Text] [Related]
20. Impact of a fixed-dose combination of naproxen and esomeprazole magnesium on serum thromboxane B2 inhibition by low-dose aspirin over 5 days in healthy adults: a phase I, randomized, double-blind, placebo-controlled, noninferiority trial.
Angiolillo DJ; Hwang C; Datto C; Desai B; Sostek M
Clin Ther; 2011 Dec; 33(12):1883-93. PubMed ID: 22078153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]